Recurrent scrotal hemangiomas during treatment with sunitinib.
Tonini
Giuseppe
G
Campus Bio-Medico University of Rome, Rome, Italy.
Intagliata
Salvatore
S
Cagli
Barbara
B
Segreto
Francesco
F
Perrone
Giuseppe
G
Onetti Muda
Andrea
A
Santini
Daniele
D
Persichetti
Paolo
P
D000970:Antineoplastic Agents / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D004164:Diphosphonates / Q000627:therapeutic use; D005834:Genital Neoplasms, Male / Q000139:chemically induced* / Q000473:pathology; D006391:Hemangioma / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects*; D012008:Recurrence; D012611:Scrotum / Q000473:pathology*; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology; D000077210:Sunitinib; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D007211:Indoles; D011758:Pyrroles; D000077211:Zoledronic Acid; D000077210:Sunitinib